RxDoctor Payments Data

Brett Fissel, MD

Family Medicine · Chalfont, PANPI 1215970694

Payments from drug & device makers

$356in general payments, 2019–2025

Across 11 payments — averaging $32.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$145
  • Inspire Medical Systems, Inc.$70
  • Johnson & Johnson$44
  • Kyowa Kirin, Inc.$24
  • Genentech USA, Inc.$23
  • Sanofi Pasteur Inc.$18
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$356 in reported general payments places this provider in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$95,453
Medicare patients
354
Services billed
849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate27$39,608
JardianceEmpagliflozin33$39,186
XareltoRivaroxaban23$31,576
EliquisApixaban15$25,184
Xtampza ErOxycodone Myristate12$14,428
Oxymorphone Hcl ErOxymorphone Hcl12$10,607
Spiriva RespimatTiotropium Bromide13$6,620
SynthroidLevothyroxine Sodium55$4,586
Atorvastatin Calcium336$4,317
Glucagon Emergency KitGlucagon15$3,781
Simvastatin228$2,635
Levothyroxine Sodium192$2,456
Rosuvastatin Calcium124$2,123
Lisinopril219$2,024
Albuterol Sulfate HfaAlbuterol Sulfate62$1,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$44$31,57623 claims
PfizerEliquis$17$25,18415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Chalfont

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →